Hypertension Management in an Elderly Patient

Clinical Scenario

Annabelle Smith, 82, has a telephone appointment to discuss her blood pressure. She has hypertension for 15 years, type 2 diabetes, CKD stage 3, a previous TIA 2 years ago, and mild cognitive impairment. She is on amlodipine 10mg, lisinopril 20mg, indapamide 2.5mg, metformin 500mg BD, and simvastatin 40mg. Her recent BP readings have been consistently above target (160/90 at the hypertension clinic). Her son helps manage her medications using a dosette box. She lives alone but her son visits daily.

What This Case Tests

Managing resistant hypertension in a complex elderly patient; adding a fourth antihypertensive agent with appropriate monitoring; navigating CKD considerations when adjusting antihypertensive therapy; involving the son as carer in medication management; balancing aggressive BP targets with the risk of overtreatment in a frail elderly patient.

Common Mistakes Trainees Make

The three most common mistakes are: simply adding a fourth agent without considering adherence (is Annabelle actually taking her current medications correctly?), not adjusting the BP target for her age and frailty (aggressive targets in frail elderly patients increase falls and adverse events), and not monitoring renal function when adjusting renin-angiotensin system medications in a patient with CKD.

The Consultation Challenge

Annabelle has resistant hypertension — BP above target despite three antihypertensive agents. Before adding a fourth, you need to address the fundamentals: is she adherent? Is the current regimen optimised? Is the BP target appropriate for her age and frailty?

Check adherence first. She has mild cognitive impairment and uses a dosette box managed by her son. Ask: is she taking all medications? Is the dosette box being filled correctly and consistently? Has she missed any doses? Non-adherence is the most common cause of apparent treatment resistance and must be excluded before escalation.

Review the BP target. NICE recommends a target of <150/90 mmHg for patients over 80, but clinical judgment is needed in frail patients with multiple comorbidities. Annabelle has CKD, cognitive impairment, and a previous TIA — lowering BP too aggressively risks postural hypotension, falls, and renal deterioration. A pragmatic target of 140-150/80-90 may be more appropriate than pushing for <130/80.

If a fourth agent is needed, NICE recommends: for resistant hypertension already on ACEi/ARB + CCB + thiazide, consider spironolactone 25mg daily (if potassium is <4.5 and eGFR >30). In Annabelle's case, CKD stage 3 requires potassium and renal function monitoring before and after starting spironolactone. An alternative is doxazosin or a beta-blocker.

Involve the son in the conversation. He manages the dosette box and visits daily — he is a crucial partner in Annabelle's care. Check he is informed about medication changes, understands the monitoring requirements, and has capacity to support the plan. Consider whether a carer's assessment is appropriate.

The cognitive impairment adds complexity. Annabelle may not fully understand or remember the medication changes. Communication should be clear, simple, and reinforced through the son. Consider whether the cognitive impairment is progressing and whether a memory clinic review is needed.

Time check: Spend the first 3 minutes on adherence assessment and current regimen review. By minute 6, discuss the BP target and whether escalation is appropriate. Address the fourth agent choice and monitoring between minutes 7-9. Involve the son in the plan between minutes 10-11. Use the final minute for follow-up arrangements.

How Examiners Mark This Case

Data Gathering and Diagnosis: Examiners assess whether you check adherence before escalating therapy, review the BP measurement technique (home versus clinic, white coat effect), assess for secondary causes if not already investigated, and review renal function and potassium before adding further agents. They also look for whether you assess the impact of cognitive impairment on self-management.

Clinical Management and Medical Complexity: Examiners expect knowledge of the fourth-line agent choice for resistant hypertension (spironolactone per NICE, with alternatives), appropriate monitoring for CKD (U&Es before and after starting, at 1-2 weeks), and an age-appropriate BP target. They look for a pragmatic approach that balances cardiovascular risk reduction with the risks of overtreatment in a frail elderly patient.

Relating to Others: Examiners assess whether you involve the son as a care partner, communicate the plan in a way that accounts for cognitive impairment (simple, clear, reinforced), and consider the broader care context (carer support, medication management, cognitive monitoring).

Example Opening

Strong opening: "Hello Annabelle, I would like to talk about your blood pressure. It has been a bit higher than we would like, and I want to make sure we are doing everything we can. First, can I check — are you managing to take all your tablets? Is the dosette box working well for you?"

When discussing targets: "At your age, we aim for a blood pressure below about 150 over 90. We do not want to push it too low because that can cause dizziness and falls. Your current reading of 160 is above that target, so I think we should add one more tablet — but I want to keep a close eye on how it affects you."

When involving the son: "Would it be helpful if I spoke to your son about the change? Since he helps with your medications, I want to make sure he knows what we are doing and what to watch for."

Avoid: "Your blood pressure is dangerously high — we need to get it down urgently." (Alarmist framing inappropriate for a chronic management discussion).

How This Appears in the SCA

Hypertension in a complex elderly patient tests your knowledge of antihypertensive escalation, CKD monitoring, age-appropriate BP targets, and multidisciplinary care. The examiner assesses whether you can balance aggressive treatment with the risks of overtreatment in a frail patient, and whether you involve the carer appropriately.

Key Statistic

Resistant hypertension (BP above target despite 3 agents including a diuretic) affects approximately 10-15% of treated hypertensive patients. In patients over 80, NICE recommends a more conservative target of <150/90 mmHg. Spironolactone 25mg daily reduces BP by approximately 8-10 mmHg systolic in resistant hypertension.

Relevant Guidelines

• NICE NG136: Hypertension in adults — diagnosis and management
• NICE CG182: Chronic kidney disease
• NICE guideline on resistant hypertension management.

Frequently Asked Questions

What is resistant hypertension and how do I manage it?

Resistant hypertension is BP above target despite optimal doses of three antihypertensive agents including a diuretic, with confirmed adherence. NICE recommends adding spironolactone 25mg daily as the fourth agent if potassium is below 4.5 mmol/L and eGFR is above 30. Alternatives include doxazosin (alpha-blocker) or bisoprolol (beta-blocker). Before escalating, always confirm adherence, check for white coat hypertension (ABPM or home monitoring), and consider secondary causes.

What BP target should I use for patients over 80?

NICE NG136 recommends a target of below 150/90 mmHg for patients aged 80 and over, which is more conservative than the under-80 target of below 140/90. In frail patients with multiple comorbidities, falls risk, and cognitive impairment, an even more conservative approach may be appropriate. The risk of overtreatment (postural hypotension, falls, renal deterioration, syncope) increases with age and frailty. Clinical judgment is essential.

What monitoring is needed when adding spironolactone in CKD?

Check U&Es (particularly potassium and creatinine/eGFR) before starting, then at 1-2 weeks, 4 weeks, and then at each dose change. Spironolactone is a potassium-sparing diuretic and can cause hyperkalaemia, particularly in CKD and when combined with ACE inhibitors or ARBs. Do not start if potassium is above 4.5 mmol/L or eGFR is below 30. Monitor for symptoms of hyperkalaemia (muscle weakness, palpitations) and renal deterioration.

How do I check adherence in a patient with cognitive impairment?

Multiple approaches: ask the patient directly (though cognitively impaired patients may not reliably report), check with the carer who manages the dosette box, review prescription collection records (are prescriptions being collected on time?), and consider blood pressure response pattern (consistently high despite multiple agents suggests non-adherence or secondary cause). If adherence is confirmed, treatment escalation is appropriate. If in doubt, directly observed therapy for a brief period can clarify.

Should I involve the carer in medication decisions for a cognitively impaired patient?

Yes — with the patient's consent. The carer is a key partner in medication management, particularly when they manage the dosette box and daily visits. Explain changes clearly to the carer, ensure they understand the monitoring requirements, and check they have capacity to support the plan. Consider a carer's assessment if the caring demands are significant. However, the patient remains the decision-maker if they have capacity for the specific decision — cognitive impairment does not automatically remove capacity.